Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 14;22(20):11061.
doi: 10.3390/ijms222011061.

The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances

James R Janopaul-Naylor  1 , Yang Shen  1 , David C Qian  1 , Zachary S Buchwald  1
Affiliations
Review

The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances

James R Janopaul-Naylor et al. Int J Mol Sci. .

Abstract

Radiotherapy has been used for more than a hundred years to cure or locally control tumors. Regression of tumors outside of the irradiated field was occasionally observed and is known as the abscopal effect. However, the occurrence of systemic anti-tumor effects was deemed too rare and unpredictable to be a therapeutic goal. Recent studies suggest that immunotherapy and radiation in combination may enhance the abscopal response. Increasing numbers of cases are being reported since the routine implementation of immune checkpoint inhibitors, showing that combined radiotherapy with immunotherapy has a synergistic effect on both local and distant (i.e., unirradiated) tumors. In this review, we summarize pre-clinical and clinical reports, with a specific focus on the mechanisms behind the immunostimulatory effects of radiation and how this is enhanced by immunotherapy.

Keywords: abscopal effect; checkpoint blockade; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proportion of patients presenting with upfront distant disease by cancer type in the period 2010–2016.
Figure 2
Figure 2
Pre-treated tumor with exhausted CD8+ T cells and tumor proliferating without immune inhibition. Radiation of tumors leads to double-stranded DNA breaks and downstream cGAS-STING signaling, which in turn increases Type 1 IFN release. Immunogenic cell death releases DAMPs such as HMGB1, HSP, GP96, and calreticulin. HMGB1 activates Dendritic Cells through TLR4-dependent pathway. Anti-CTLA-4 agents act on naïve and regulatory T cells while anti-PD-1 agents predominantly work on exhausted T cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Connell P.P., Hellman S. Advances in radiotherapy and implications for the next century: A historical perspective. Cancer Res. 2009;69:383–392. doi: 10.1158/0008-5472.CAN-07-6871. - DOI - PubMed
    1. McKeown S.R., Hatfield P., Prestwich R.J.D., Shaffer R.E., Taylor R.E. Radiotherapy for benign disease; Assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br. J. Radiol. 2015;88:433–435. doi: 10.1259/bjr.20150405. - DOI - PMC - PubMed
    1. Baskar R., Lee K.A., Yeo R., Yeoh K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012;9:193–199. doi: 10.7150/ijms.3635. - DOI - PMC - PubMed
    1. Mole R.H. Whole body irradiation; radiobiology or medicine? Br. J. Radiol. 1953;26:234–241. doi: 10.1259/0007-1285-26-305-234. - DOI - PubMed
    1. Abuodeh Y., Venkat P., Kim S. Systematic review of case reports on the abscopal effect. Curr. Probl. Cancer. 2016;40:25–37. doi: 10.1016/j.currproblcancer.2015.10.001. - DOI - PubMed

LinkOut - more resources